BioDelivery Sciences International (BDSI) Issues Earnings Results

BioDelivery Sciences International (NASDAQ:BDSI) released its quarterly earnings data on Thursday, March 15th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05), Bloomberg Earnings reports. BioDelivery Sciences International had a net margin of 8.52% and a return on equity of 22.93%. The company had revenue of $12.51 million during the quarter, compared to analyst estimates of $9.83 million.

NASDAQ BDSI traded down $0.05 during trading hours on Friday, hitting $2.10. 284,601 shares of the stock were exchanged, compared to its average volume of 463,167. The stock has a market capitalization of $125.67, a P/E ratio of -5.38 and a beta of 0.44. BioDelivery Sciences International has a 12-month low of $1.55 and a 12-month high of $3.60. The company has a quick ratio of 1.29, a current ratio of 1.52 and a debt-to-equity ratio of 5.37.

How to Become a New Pot Stock Millionaire

BDSI has been the subject of several recent research reports. HC Wainwright set a $4.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Monday, March 19th. Cantor Fitzgerald reiterated a “buy” rating and set a $5.00 target price on shares of BioDelivery Sciences International in a research note on Thursday, March 15th. ValuEngine downgraded shares of BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Zacks Investment Research upgraded shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Wednesday, February 14th. Finally, Seaport Global Securities initiated coverage on shares of BioDelivery Sciences International in a research note on Friday, January 26th. They set a “buy” rating and a $5.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $4.25.

In related news, CFO Paolantonio Ernest Robert De sold 64,155 shares of the stock in a transaction dated Friday, April 6th. The shares were sold at an average price of $2.09, for a total transaction of $134,083.95. Following the completion of the transaction, the chief financial officer now directly owns 97,731 shares of the company’s stock, valued at $204,257.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark A. Sirgo sold 108,000 shares of the stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $2.57, for a total transaction of $277,560.00. Following the transaction, the director now directly owns 1,759,262 shares of the company’s stock, valued at $4,521,303.34. The disclosure for this sale can be found here. Insiders have sold 995,533 shares of company stock valued at $2,592,279 over the last three months. 9.00% of the stock is currently owned by corporate insiders.

A hedge fund recently raised its stake in BioDelivery Sciences International stock. Northern Trust Corp raised its stake in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) by 0.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 140,450 shares of the specialty pharmaceutical company’s stock after buying an additional 1,203 shares during the period. Northern Trust Corp owned approximately 0.25% of BioDelivery Sciences International worth $394,000 at the end of the most recent reporting period. 45.82% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “BioDelivery Sciences International (BDSI) Issues Earnings Results” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/biodelivery-sciences-international-bdsi-announces-earnings-results-misses-expectations-by-0-05-eps.html.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Earnings History for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply